Identifying immunodominant multi-epitopes from the envelope glycoprotein of the Lassa mammarenavirus as vaccine candidate for Lassa fever
© Korean Vaccine Society..
Purpose: Lassa fever is a zoonotic acute viral hemorrhagic disease caused by Lassa virus (LASV). There is currently no licensed vaccine for the prevention of the disease. This study is aimed at discovering immunodominant epitopes from the envelope glycoprotein of the Lassa mammarenavirus and designing of a multi-epitope vaccine candidate (VC).
Materials and Methods: The amino acid sequences of the envelope glycoprotein of 26 strains of LASV from five countries were selected. After evaluation for antigenicity, immunogenicity, allergenicity, and toxicity, immunodominant CD8, CD4, and linear B lymphocytes were also selected. The selected epitopes were modelled and a molecular docking with the appropriate major histocompatibility complex (MHC) proteins was performed. Using an adjuvant and linkers, a multi-epitope VC was designed. The VC was evaluated for its physicochemical and immunological properties and structurally refined, validated, and mutated (disulphide engineering). The complex formed by the VC and the toll-like receptor-4 receptor was subjected to molecular dynamic simulation (MDS) followed by in silico cloning in a plasmid vector.
Results: A VC with 203 sequences, 22.13 kDa weight, isoelectric point of 9.85 (basic), instability index value of 27.62, aliphatic index of 68.87, and GRAVY value of -0.455 (hydrophilic) emerged. The VC is predicted to be non-allergenic with antigenicity, MHC I immunogenicity, and solubility upon overexpression values of 0.81, 2.04, and 0.86 respectively. The VC also has an estimated half-life greater than 10 hours in Escherichia coli and showed stability in all the parameters of MDS.
Conclusion: The VC shows good promise in the prevention of Lassa fever but further tests are required to validate its safety and efficacy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Clinical and experimental vaccine research - 11(2022), 3 vom: 30. Sept., Seite 249-263 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rowaiye, Adekunle Babajide [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Envelope protein |
|---|
| Anmerkungen: |
Date Revised 02.12.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7774/cevr.2022.11.3.249 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349643407 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349643407 | ||
| 003 | DE-627 | ||
| 005 | 20231226043122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7774/cevr.2022.11.3.249 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349643407 | ||
| 035 | |a (NLM)36451670 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rowaiye, Adekunle Babajide |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identifying immunodominant multi-epitopes from the envelope glycoprotein of the Lassa mammarenavirus as vaccine candidate for Lassa fever |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © Korean Vaccine Society. | ||
| 520 | |a Purpose: Lassa fever is a zoonotic acute viral hemorrhagic disease caused by Lassa virus (LASV). There is currently no licensed vaccine for the prevention of the disease. This study is aimed at discovering immunodominant epitopes from the envelope glycoprotein of the Lassa mammarenavirus and designing of a multi-epitope vaccine candidate (VC) | ||
| 520 | |a Materials and Methods: The amino acid sequences of the envelope glycoprotein of 26 strains of LASV from five countries were selected. After evaluation for antigenicity, immunogenicity, allergenicity, and toxicity, immunodominant CD8, CD4, and linear B lymphocytes were also selected. The selected epitopes were modelled and a molecular docking with the appropriate major histocompatibility complex (MHC) proteins was performed. Using an adjuvant and linkers, a multi-epitope VC was designed. The VC was evaluated for its physicochemical and immunological properties and structurally refined, validated, and mutated (disulphide engineering). The complex formed by the VC and the toll-like receptor-4 receptor was subjected to molecular dynamic simulation (MDS) followed by in silico cloning in a plasmid vector | ||
| 520 | |a Results: A VC with 203 sequences, 22.13 kDa weight, isoelectric point of 9.85 (basic), instability index value of 27.62, aliphatic index of 68.87, and GRAVY value of -0.455 (hydrophilic) emerged. The VC is predicted to be non-allergenic with antigenicity, MHC I immunogenicity, and solubility upon overexpression values of 0.81, 2.04, and 0.86 respectively. The VC also has an estimated half-life greater than 10 hours in Escherichia coli and showed stability in all the parameters of MDS | ||
| 520 | |a Conclusion: The VC shows good promise in the prevention of Lassa fever but further tests are required to validate its safety and efficacy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Envelope protein | |
| 650 | 4 | |a Epitopes | |
| 650 | 4 | |a Lassa virus | |
| 650 | 4 | |a Major histocompatibility complex | |
| 650 | 4 | |a Vaccine candidate | |
| 700 | 1 | |a Nwonu, Ezinne Janefrances |e verfasserin |4 aut | |
| 700 | 1 | |a Asala, Titilayo Mercy |e verfasserin |4 aut | |
| 700 | 1 | |a Ogu, Amoge Chidinma |e verfasserin |4 aut | |
| 700 | 1 | |a Bur, Doofan |e verfasserin |4 aut | |
| 700 | 1 | |a Chukwu, Chimaobi |e verfasserin |4 aut | |
| 700 | 1 | |a Oli, Angus Nnamdi |e verfasserin |4 aut | |
| 700 | 1 | |a Agbalalah, Tarimoboere |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental vaccine research |d 2012 |g 11(2022), 3 vom: 30. Sept., Seite 249-263 |w (DE-627)NLM226777731 |x 2287-3651 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:3 |g day:30 |g month:09 |g pages:249-263 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7774/cevr.2022.11.3.249 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 3 |b 30 |c 09 |h 249-263 | ||